Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Hypertriglyceridemia

Hypertriglyceridemia

Hypertriglyceridemia is a metabolic disorder characterized by elevated levels of triglycerides in the bloodstream.
This condition is often associated with an increased risk of cardiovascular disease and pancreatitis.
Identifying effective research protocols is crucial for understanding and managing hypertriglyceridemia.
PubCompare.ai's AI-driven tool can help optimize your research by easily locating relevant protocols from literature, preprints, and patents, while leveraging AI comparisons to identify the most reproducible and accurrate approaches.
Improve your research outcomes with PubCompare.ai's powerful platform.

Most cited protocols related to «Hypertriglyceridemia»

1
Randomized Trial of Menopausal Hormone Therapy
KEEPS was designed as a randomized, placebo-controlled, double-blinded, prospective trial (KEEPS; NCT000154180) to evaluate effects of MHT on progression of atherosclerosis as defined by carotid intima–media thickness (CIMT) [44 (link)] and coronary arterial calcification (CAC) [8 (link), 73 (link)] in women who more closely match the age of initiation of MHT reported by prior observational studies. Women meeting inclusion criteria subsequently were randomized to daily placebo, oral CEE, or transdermal 17β-estradiol with placebo or pulsed progesterone for 12 days/month. The detailed inclusion and exclusion criteria for KEEPS have been published elsewhere [36 (link)]. In brief, women between the ages of 42 and 58 years of age who were at least 6 months and no more than 36 months from their last menses with plasma follicle-stimulating hormone (FSH) level ≥35 ng/mL and/or E2 levels <40 pg/mL were eligible. A history of clinical CVD including myocardial infarction, angina, congestive heart failure, or thromboembolic disease excluded women from KEEPS. Other major cardiovascular risk factors excluding participation were current heavy smoking (more than ten cigarettes/day by self-report), morbid obesity [body mass index (BMI) >35 mm2/kg], dyslipidemia (LDL cholesterol >190 mg/dL), hypertriglyceridemia (triglycerides >400 mg/dL), and uncontrolled hypertension (systolic blood pressure >150 mm Hg and/or diastolic blood pressure >95 mm Hg) and glucose >126 mg/dL. Complete blood count and chemistry panel, estradiol, and FSH were performed at the clinical laboratories at each recruiting center. Lipid profiles and thyroid-stimulating hormone (TSH) were performed at the Kronos Science Laboratories (Phoenix, AZ, USA). At screening, women were asked to rank their menopausal symptoms (hotflashes, night sweats, vaginal dryness, dyspareunia, palpitations, insomnia, depression, mood swings, and irritability) as either none, mild, moderate, or severe. Finally, all subjects were screened for CAC and women with Agatston score ≥50 U, indicating significant subclinical coronary artery disease, were excluded. All women meeting inclusion criteria underwent baseline measurements of CIMT by B-mode ultrasound [44 (link)]. All imaging results are read centrally by individuals blinded to participant demographics (CAC at the Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA under the direction of Dr. M. Budoff and CIMT at the Atherosclerosis Research Unit Core Imaging and Reading Center, University of Southern California, Los Angeles, CA, USA under the direction of Dr. H. Hodis).
Analysis of variance was used to determine statistical significance except where an alternative test is specified. Statistical significance was accepted at P < 0.05.
Miller V.M., Black D.M., Brinton E.A., Budoff M.J., Cedars M.I., Hodis H.N., Lobo R.A., Manson J.E., Merriam G.R., Naftolin F., Santoro N., Taylor H.S, & Harman S.M. (2009). Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Journal of Cardiovascular Translational Research, 2(3), 228-239.
Publication 2009
Angina Pectoris Artery, Coronary Atherosclerosis Calcinosis Carotid Intima-Media Thickness Cholesterol, beta-Lipoprotein Clinical Laboratory Services Complete Blood Count Comprehensive Metabolic Panel Congestive Heart Failure Coronary Arteriosclerosis Desiccation Disease Progression Dyslipidemias Estradiol Glucose High Blood Pressures Human Follicle Stimulating Hormone Hypertriglyceridemia Index, Body Mass Lipids Menopause Menstruation Mood Myocardial Infarction Obesity, Morbid Placebos Plasma Pressure, Diastolic Progesterone Sleeplessness Sweat Systolic Pressure Thromboembolism Thyrotropin Triglycerides Ultrasonography Vagina Woman
2
Genetics of Premature Coronary Artery Disease
The study complies with the Declaration of Helsinki and was approved by the Ethics Committee of the Instituto Nacional de Cardiología Ignacio Chávez (INCICH). All participants provided written informed consent. The study included 1162 patients with premature CAD and 873 healthy controls belonging to the Genetics of Atherosclerotic Disease (GEA) Mexican Study. Premature CAD was defined as history of myocardial infarction, angioplasty, revascularization surgery, or coronary stenosis > 50% on angiography, diagnosed before age of 55 in men and before age of 65 in women. Controls were apparently healthy asymptomatic individuals without family history of premature CAD, recruited from blood bank donors and through brochures posted in Social Service centers. Chest and abdomen computed tomographies were performed using a 64-channel multidetector helical computed tomography system (Somatom Sensation, Siemens) and interpreted by experienced radiologists. Scans were read to assess and quantify the following: (1) coronary artery calcification (CAC) score using the Agatston method [20 (link)] and (2) total adipose tissue (TAT) and subcutaneous and visceral adipose tissue areas (SAT and VAT) as described by Kvist et al. [21 (link)]. For the present study, the control group only included individuals with CAC = 0, who were nondiabetic, and with normal glucose levels (n = 873). In the whole sample, the demographic, clinical, anthropometric, and biochemical parameters and cardiovascular risk factors were evaluated and defined as previously described [22 –24 (link)]. Briefly, hypercholesterolemia was defined as total cholesterol (TC) levels ≥ 200 mg/dL. Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or the use of oral antihypertensive therapy. Type 2 diabetes mellitus (T2DM) was defined with a fasting glucose ≥ 126 mg/dL and was also considered when participants reported glucose-lowering treatment or a physician diagnosis of T2DM. Obesity was defined as body mass index (BMI) ≥ 30 kg/m2. Hypoalphalipoproteinemia, hypertriglyceridemia, and metabolic syndrome (MS) were defined using the criteria from the American Heart Association, National Heart, Lung, and Blood Institute Scientific Statement [25 (link)], except for central obesity that was considered when waist circumference was 90 cm in men and 80 cm in women [26 (link)]. Hyperuricemia was considered with a serum uric acid > 6.0 mg/dL and >7.0 mg/dL for women and men, respectively [27 (link)]. Insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR). The presence of insulin resistance was considered when the HOMA-IR values were ≥75th percentile (3.66 in women and 3.38 in men). Hyperinsulinemia was defined when insulin concentration was ≥75th percentile (16.97 μIU/mL in women and 15.20 μIU/mL in men). Hypoadiponectinemia was defined when adiponectin concentration was ≤25th percentile (8.67 μg/mL in women and 5.30 μg/mL in men). Increased VAT was defined as VAT ≥ 75th percentile (122.0 cm2 in women and 151.5 cm2 in men) and increased SAT as SAT ≥ 75th percentile (335.5 cm2 in women and 221.7 cm2 in men). Elevated alanine aminotransferase (ALT) was defined as ALT activity ≥ 75th percentile (21.0 IU/L in women and 24.5 IU/L in men). Elevated aspartate aminotransferase (AST) was defined as AST activity ≥ 75th percentile (25 IU/L in women and 28 IU/L in men) and elevated gamma glutamyltransferase (GGT) was defined as GGT ≥ 75th percentile (21.0 IU/L in women and 27.5 IU/L in men). These cutoff points were obtained from a GEA study sample of 131 men and 185 women without obesity and with normal values of blood pressure, fasting glucose, and lipids.
All GEA participants are unrelated and of self-reported Mexican-Mestizo ancestry (three generations). In order to establish the ethnical characteristics of the studied groups, we analyzed 265 ancestry informative markers (AIMs). Using the ADMIXTURE software, the Caucasian, Amerindian, and African backgrounds were determined. Similar background in premature CAD patients and healthy controls was found (P > 0.05). Patients showed 55.8% of Amerindian ancestry, 34.3% of Caucasian ancestry, and 9.8% of African ancestry, whereas controls showed 54.0% of Amerindian ancestry, 35.8% of Caucasian ancestry, and 10.1% of African ancestry.
Posadas-Sánchez R., Pérez-Hernández N., Angeles-Martínez J., López-Bautista F., Villarreal-Molina T., Rodríguez-Pérez J.M., Fragoso J.M., Posadas-Romero C, & Vargas-Alarcón G. (2017). Interleukin 35 Polymorphisms Are Associated with Decreased Risk of Premature Coronary Artery Disease, Metabolic Parameters, and IL-35 Levels: The Genetics of Atherosclerotic Disease (GEA) Study. Mediators of Inflammation, 2017, 6012795.
Full text: Click here
Publication 2017
Abdomen Adiponectin Angiography Angioplasty Antihypertensive Agents Artery, Coronary Aspartate Transaminase BLOOD Blood Pressure Calcinosis Chest Cholesterol Coronary Stenosis D-Alanine Transaminase Diabetes Mellitus, Non-Insulin-Dependent Diagnosis Donor, Blood Ethics Committees gamma-Glutamyl Transpeptidase Glucose Heart Hereditary Diseases High Blood Pressures Homeostasis Hypercholesterolemia Hyperinsulinism Hypertriglyceridemia Hyperuricemia Hypoadiponectinemia Hypoalphalipoproteinemias Index, Body Mass Insulin Insulin Resistance Lipids Lung Metabolic Syndrome X Multiple Endocrine Neoplasia Type 2b Myocardial Infarction Negroid Races Obesity Operative Surgical Procedures Patients Physicians Premature Birth Pressure, Diastolic Radiologist Radionuclide Imaging Serum Subcutaneous Fat Systolic Pressure Tissue, Adipose Tomography, Spiral Computed Uric Acid Waist Circumference White Person Woman X-Ray Computed Tomography
3
Tehran Cardiometabolic Genetic Study
The TCGS is a prospective family-based GWAS cohort that has been followed since 1999 within the Tehran Lipid and Glucose Study (TLGS), which includes over 15,000 initially healthy subjects >3 years old, who have already been followed for more than 20 years. Participants have been followed for the development of common disorders such as myocardial infarction, stroke, diabetes mellitus, hypertension, obesity, familial hypercholesterolemia, hyperlipidemia, habitation (eg, smoking and physical activity), and biochemical factors (ie, high cholesterol, low high-density lipoproteins, high triglycerides).
The concept of designing a genomic bank from TLGS samples was first presented to the Endocrine Research Center (ERC) and the Iranian molecular medicine network, and was funded by FA and MSD (grant number 147, 2004; grant number 265, 2008). In 2008, a project determining pedigrees according to genetic relationships was funded by ERC (grant number 321), with MSD and AAM as principal investigators. Funding of the main study began in June 2012 with an agreement between the Research Institute for Endocrine Sciences (RIES) and the deCODE genetic company (Reykjavik, Iceland), with FA and MSD as primary investigators. The final protocol for the genetic study was written by FA, MSD, MSF, and DK, and was submitted to the Ministry of Health and Medical Education in August 2012. The protocol was approved by the National Committee for Ethics in Biomedical Research in December 2012.
In this paper, we describe the TCGS (and its parent TLGS) from the perspectives of cohort assembly, follow-up, endpoint validation, baseline plasma phenotyping, DNA extraction, genotyping, participant confidentiality, power, and sample size, and discuss the TCGS in the context of other ongoing GWASs being performed in related areas. The study is organized into 5 phases: (1) cohort assembly and prospective follow-up, (2) genomic sample extraction, (3) phenotype and outcome gathering, (4) chip typing and genotype analysis, and (5) drawing family trees.
Daneshpour M.S., Fallah M.S., Sedaghati-Khayat B., Guity K., Khalili D., Hedayati M., Ebrahimi A., Hajsheikholeslami F., Mirmiran P., Ramezani Tehrani F., Momenan A.A., Ghanbarian A., Amouzegar A., Amiri P, & Azizi F. (2017). Rationale and Design of a Genetic Study on Cardiometabolic Risk Factors: Protocol for the Tehran Cardiometabolic Genetic Study (TCGS). JMIR Research Protocols, 6(2), e28.
Full text: Click here
Publication 2017
Cerebrovascular Accident Developmental Disabilities Diabetes Mellitus DNA Chips Education, Medical Genome Genome-Wide Association Study Genotype Glucose Healthy Volunteers High Blood Pressures High Density Lipoproteins Hypercholesterolemia Hyperlipidemia Hyperlipoproteinemia Type IIa Hypertriglyceridemia Lipid A Lipids Low-Density Lipoproteins Myocardial Infarction Obesity Parent Phenotype Plasma Reproduction System, Endocrine
4
Cardiometabolic Risk Factors in Children
WC was measured at the narrowest point between the lower borders of the rib cage and the iliac crest at the end of normal expiration. WHtR was calculated by dividing WC (cm) by height (cm), and the WHtR cutoff of 0.5 was used, as it was previously suggested as a universal WHtR cutoff.12 (link) Central obesity was defined by WC ≥90th percentile using Korean waist reference data for those of <16 years of age.15 For those ≥16 years of age, a WC of ≥90 cm in boys and of ≥85 cm in girls was used to define central obesity, according to the Korean-specific WC cutoff points.16 (link)
Hypertension was defined by systolic blood pressure (SBP) ≥130 mm Hg or diastolic BP (DBP) ≥85 mm Hg. Hyperglycemia was defined by fasting glucose ≥100 mg/dL, and hypertriglyceridemia was defined by fasting triglyceride level ≥150 mg/dL. Decreased HDL-C was defined as an HDL-C level of <40 mg/dL for all boys and girls of <16 years of age and of <50 mg/dL in girls of ≥16 years of age.14 (link) The presence of two or more CMRFs among hypertension, hyperglycemia, hypertriglyceridemia, and decreased HDL-C was classified as multiple CMRFs.
Metabolic syndrome was defined by the International Diabetes Federation (IDF) criteria for children and adolescents.14 (link) A WC of at least the 90th percentile using Korean waist reference data15 was a mandatory criterion for metabolic syndrome. For those of at least 16 years, a WC of ≥90 cm in boys or of ≥85 cm in girls was used to define central obesity.16 (link) Two or more of the following components were also required: a fasting triglyceride level of 150 mg/dL, a fasting glucose concentration of 100 mg/dL or specific treatment, SBP of 130 mm Hg or DBP of 85 mm Hg, or an HDL-C level of <40 mg/dL for both boys and girls of <16 years or of <50 mg/dL in girls of ≥16 years.
Chung I.H., Park S., Park M.J, & Yoo E.G. (2016). Waist-to-Height Ratio as an Index for Cardiometabolic Risk in Adolescents: Results from the 1998-2008 KNHANES. Yonsei Medical Journal, 57(3), 658-663.
Publication 2016
Adolescent Boys Child Costal Arch Diabetes Mellitus Glucose High Blood Pressures Hyperglycemia Hypertriglyceridemia Iliac Crest Koreans Metabolic Syndrome X Pressure, Diastolic Systolic Pressure Triglycerides Woman
5
Genetic Scoring of Insulin Resistance and Secretion
We created unweighted (i.e. per-allele) genetic risk scores for insulin resistance and impaired insulin secretion using effect alleles defined from the literature as shown in Supplementary Table 1. The insulin resistance genetic score comprised variants associated with fasting insulin in recent meta-analyses (8 (link)). In order to improve specificity we restricted the insulin resistance score to the 10 variants showing association (p<0.05) with lower HDL and higher triglycerides (8 (link),16 (link)): a hallmark of common insulin resistance. This excluded TCF7L2, associated principally with insulin secretion (17 ), and FTO, whose effect on insulin levels was entirely mediated by BMI (8 (link)). Variants included were those in or near the IRS1, GRB14, ARL15, PPARG, PEPD, ANKRD55/MAP3K1, PDGFC, LYPLAL1, RSPO3, and FAM13A1 genes (Supplementary Table 1). For the insulin secretion score, from loci associated with T2D and related traits (18 (link)-21 (link)) we undertook literature searches to identify SNPs showing an association with impaired early insulin secretion. In addition, we investigated the literature to identify additional candidate genes associated with early insulin secretion. Up to 21 variants associated with decreased early insulin secretion were included in the insulin secretion score. Where SNPs were missing, we included a proxy where available (Supplementary Table 1), and where no proxy was available, we did not impute missing SNPs. Each SNP, the reason for inclusion in the score and its availability in each study is shown in Supplementary Table 1. The genetic score distributions in each study are shown in for the insulin secretion and insulin resistance scores in Supplementary Figure 2a and b, respectively.
Scott R.A., Fall T., Pasko D., Barker A., Sharp S.J., Arriola L., Balkau B., Barricarte A., Barroso I., Boeing H., Clavel-Chapelon F., Crowe F.L., Dekker J.M., Fagherazzi G., Ferrannini E., Forouhi N.G., Franks P.W., Gavrila D., Giedraitis V., Grioni S., Groop L.C., Kaaks R., Key T.J., Kühn T., Lotta L.A., Nilsson P.M., Overvad K., Palli D., Panico S., Quirós J.R., Rolandsson O., Roswall N., Sacerdote C., Sala N., Sánchez M.J., Schulze M.B., Siddiq A., Slimani N., Sluijs I., Spijkerman A.M., Tjonneland A., Tumino R., van der A D.L., Yaghootkar H., McCarthy M.I., Semple R.K., Riboli E., Walker M., Ingelsson E., Frayling T.M., Savage D.B., Langenberg C, & Wareham N.J. (2014). Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independently of obesity. Diabetes, 63(12), 4378-4387.
Publication 2014
Alleles Genes Genetic Diversity GRB14 protein, human Hypertriglyceridemia Insulin Insulin Resistance Insulin Secretion IRS1 protein, human MAP3K1 protein, human Paroxysmal Extreme Pain Disorder platelet derived growth factor C, human Reproduction TCF7L2 protein, human

Most recents protocols related to «Hypertriglyceridemia»

1
Metabolic Health in Obesity: A Classification
Obesity and abdominal obesity were defined as a BMI of 30.0 or more and a waist circumference of 102 cm or more for men and 88 cm or more for women. The ethnicity-specific BMI cutoff for non-Hispanic Asian individuals was not used due to the lack of classification of this subgroup in the NHANES before 2011.24 Metabolic health was defined according to the harmonized definition proposed by Lavie et al17 (link) and Ortega et al.18 (link) Adults with obesity were classified as having MHO if they had 0 of 4 MetS components29 (link),30 (link): (1) elevated BP (systolic BP ≥130 mm Hg, diastolic BP ≥85 mm Hg, or antihypertensive medication use); (2) elevated FPG (≥100 mg/dL [to convert to millimoles per liter, multiply by 0.0555] or antidiabetic medication use); (3) reduced high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL for men and <50 mg/dL for women [to convert to millimoles per liter, multiply by 0.0259]); or (4) elevated triglycerides (≥150 mg/dL [to convert to millimoles per liter, multiply by 0.0113]). Waist circumference was excluded for collinearity with BMI. Since data for cholesterol medication were available only for general use but not for treatment of elevated triglycerides or reduced HDL-C specifically, we did not utilize this information to avoid overestimation of these components, consistent with previous reports on MetS.31 (link) Participants with obesity who met any of the above criteria were classified as having MUO.
Wang J.S., Xia P.F., Ma M.N., Li Y., Geng T.T., Zhang Y.B., Tu Z.Z., Jiang L., Zhou L.R., Zhang B.F., Tong W.W., Shan Z., Liu G., Yang K, & Pan A. (2023). Trends in the Prevalence of Metabolically Healthy Obesity Among US Adults, 1999-2018. JAMA Network Open, 6(3), e232145.
Full text: Click here
Publication 2023
Adult Antidiabetics Antihypertensive Agents Asian Americans Cholesterol Ethnicity High Density Lipoprotein Cholesterol Hispanics Hypertriglyceridemia Obesity Pharmaceutical Preparations Pressure, Diastolic Systolic Pressure Waist Circumference Woman
2
Metabolic and Thyroid Dysfunction Evaluation
Blood samples were collected in the morning after an overnight fast before participants received any medical treatment. Serum levels of free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), antithyroglobulin (TgAb), thyroid peroxidase antibody (TPOAb), TC, TG, high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), and glucose were assessed. Lipid markers (TC, TG, HDL-C, LDL-C) and glucose were measured on a Cobas E610 (Roche, Basel, Switzerland). Thyroid hormones were assayed on a Roche C6000 Electrochemiluminescence Immunoassay Analyzer (Roche Diagnostics, Indianapolis, IN, USA). Measurements were conducted in the laboratory of the First Hospital, Shanxi Medical University. The nurses measured the patients’ weight, height, and blood pressure. We calculated body mass index (BMI) according to the following formula: BMI = Weight (kg)/Height (m) 2.
According to previous studies in the Chinese population (38 (link), 39 (link)), metabolic disturbances and thyroid dysfunction were defined as follows: (1) overweight or obesity: BMI≥24; (2) hyperglycemia: glucose≥6.1mmol/L; (3) hypertension: SBP≥140 mmHg and/or DBP≥90mmHg; (4) hypertriglyceridemia: TG≥2.3 mmol/L; (5) low HDL: HDL-C ≤ 1.0 mmol/L; (6) hypercholesterolemia: TC≥6.2 mmol/L or LDL-C≥4.1 mmol/L; (7)abnormal TgAb: TgAb≥115 IU/L; (8) abnormal TPOAb: TPOAb ≥34 IU/L; (9) subclinical hypothyroidism (SCH): TSH >4.2 mIU/L with normal fT4 concentration (10–23 pmol/L); (10) hyperthyroidism: TSH<0.27 mIU/L and FT4 >23 pmol/L, and (11) hypothyroidism: TSH >4.2 mIU/L with low FT4 concentration (<10 pmol/L).
Peng P., Wang Q., Lang X., Liu T, & Zhang X.Y. (2023). Clinical symptoms, thyroid dysfunction, and metabolic disturbances in first-episode drug-naïve major depressive disorder patients with suicide attempts: A network perspective. Frontiers in Endocrinology, 14, 1136806.
Full text: Click here
Publication 2023
anti-thyroglobulin antibody BLOOD Blood Pressure Chinese Diagnosis Glucose High Blood Pressures high density lipoprotein-1 High Density Lipoproteins Hypercholesterolemia Hyperglycemia Hyperthyroidism Hypertriglyceridemia Hypothyroidism Immunoassay Index, Body Mass LDL-1 Liothyronine Lipids Low-Density Lipoproteins Nurses Obesity Patients Serum Thyroid Gland Thyroid Hormones thyroid microsomal antibodies Thyrotropin Thyroxine
3
Anemia, Diabetes, and Cardiometabolic Profiles
Anemia was considered as hemoglobin less than 12 g/dL in women and less than 13 g/dL in men according to the World Health Organization (WHO) criteria (12). DM was defined as FPG ≥ 126 mg/dL and/or Hb A1c ≥ 6.5 or taking any GLDs. The participants were categorized into two groups: BMI < 30 kg/m2 (normal/overweight) and ≥ 30 kg/m2 (obese). Chronic kidney disease (CKD) was considered as e-GFR lower than 60 mL/ min/1.73m2 according to the kidney disease outcomes quality initiative (KDQOI) guidelines [17 (link)]. Albuminuria was considered as urinary albumin creatinine ratio (ACR) of 30 mg or more in 24 hours’ urine collection. Hypertriglyceridemia was defined as TG more than 150 mg/dL and hypercholesterolemia was considered TC more than 200 mg/dL.
Hizomi Arani R., Fakhri F., Naeimi Tabiee M., Talebi F., Talebi Z., Rashidi N, & Zahedi M. (2023). Prevalence of anemia and its associated factors among patients with type 2 diabetes mellitus in a referral diabetic clinic in the north of Iran. BMC Endocrine Disorders, 23, 58.
Full text: Click here
Publication 2023
Albumins Anemia Cell Leukodystrophy, Globoid Chronic Kidney Diseases Creatinine Hemoglobin Hemoglobin A, Glycosylated Hypercholesterolemia Hypertriglyceridemia Kidney Diseases Obesity Urine Urine Specimen Collection Woman
4
Anemia Prevalence and Associated Factors
Statistical analyses were performed using SPSS version 21 for Windows (Chicago, Illinois, USA). To report the quantitative variables, mean (standard deviation: SD) and median (inter-quartile range) were used for variables with normal and highly skewed distribution, respectively. To compare baseline characteristics of quantitative variables between anemic and non-anemic groups, the t-test and the Mann-Whitney test were used for variables with normal and highly skewed distribution, respectively. The prevalence [95% confidence interval (CI)] of each group of categorical variables were estimated and compared by Chi-square test.
The univariable and multivariable logistic regression analyses were performed for categorical variables to evaluate thet association between variables and anemia by reporting odds ratios (ORs) with 95% CI. Only covariates with a p-value <0.20 in the univariable analysis were then selected to enter the multivariable analysis. The multivariable model is adjusted for obesity status, Hb A1c (Hb A1c ≤ 7% as reference), T2DM duration (less than five years as reference), GLDs usage (oral as reference), prevalent CKD, prevalent albuminuria, hypertriglyceridemia, and hypercholesterolemia .
Hizomi Arani R., Fakhri F., Naeimi Tabiee M., Talebi F., Talebi Z., Rashidi N, & Zahedi M. (2023). Prevalence of anemia and its associated factors among patients with type 2 diabetes mellitus in a referral diabetic clinic in the north of Iran. BMC Endocrine Disorders, 23, 58.
Full text: Click here
Publication 2023
Anemia Cell Leukodystrophy, Globoid Hemoglobin A, Glycosylated Hypercholesterolemia Hypertriglyceridemia Obesity
5
Diagnostic Criteria for Metabolic Disorders
The criteria recommended by the Chinese Diabetes Society (25 (link)) were used to diagnose hypertriglyceridemia (triglyceride level≥1.70 mmol/L), reduced HDL-C (HDL-C level<1.04 mmol/L), hypertension (systolic blood pressure≥130 mmHg, diastolic blood pressure≥ 85 mmHg, or use of antihypertensive medications), and hyperglycemia (fasting plasma glucose level ≥6.1 mmol/L or use of antidiabetic medications).
Yang M., Zhang Y., Zhao W., Ge M., Sun X., Zhang G, & Dong B. (2023). Individual and combined associations of body mass index and waist circumference with components of metabolic syndrome among multiethnic middle-aged and older adults: A cross-sectional study. Frontiers in Endocrinology, 14, 1078331.
Full text: Click here
Publication 2023
Antidiabetics Antihypertensive Agents Chinese Diabetes Mellitus Diagnosis Glucose High Blood Pressures Hyperglycemia Hypertriglyceridemia Plasma Pressure, Diastolic Systolic Pressure Triglycerides

Top products related to «Hypertriglyceridemia»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Spss version 22 by IBM
Sourced in United States, Japan, United Kingdom, Austria, Germany, Czechia, Belgium, Denmark, Canada
SPSS version 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data for research and business purposes. The software provides a range of statistical analysis tools and techniques, including regression analysis, hypothesis testing, and data visualization.
3
Au680 by Beckman Coulter
Sourced in United States, Germany, Japan, United Kingdom
The AU680 is an automated clinical chemistry analyzer designed for high-throughput clinical laboratory testing. It features a modular design, advanced analytical technologies, and comprehensive test menu capabilities to provide efficient and reliable results.
4
Cobas c501 by Roche
Sourced in Switzerland, Germany, United States, Japan, Denmark, France, Sweden
The Cobas c501 is a clinical chemistry analyzer developed by Roche. It is designed for routine and specialized in vitro diagnostic testing in a laboratory setting. The Cobas c501 performs a wide range of biochemical and immunochemical analyses on various sample types.
5
Elecsys 2010 by Roche
Sourced in Germany, Switzerland, United States, United Kingdom, France, Norway, Japan
The Elecsys 2010 is an automated immunoassay analyzer used for the in vitro determination of various analytes in biological samples. It is designed for high-throughput testing and offers precise and reliable results.
6
Intralipid by Baxter
Sourced in United States
Intralipid is a sterile, non-pyrogenic, lipid emulsion for intravenous administration. It is composed of a 10% or 20% soybean oil, 1.2% egg yolk phospholipids, and 2.25% glycerin in water. Intralipid provides a source of calories and essential fatty acids for patients who cannot maintain adequate nutrition through oral or enteral intake.
7
Kge014 by R&D Systems
Sourced in United States
KGE014 is a lab equipment product manufactured by R&D Systems. It is designed for general laboratory use, but the specific core function of this product is not available in the given information. A detailed and unbiased description could not be provided while maintaining the required level of conciseness and objectivity.
8
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
9
Cobas 8000 analyzer by Roche
Sourced in Switzerland, Germany, United States, France
The Cobas 8000 analyzer is a modular, automated in-vitro diagnostic system designed for high-throughput clinical laboratory testing. It is capable of performing a variety of clinical chemistry and immunochemistry assays. The Cobas 8000 analyzer combines multiple analytical modules to provide an integrated solution for efficient and reliable sample processing and analysis.
10
Spss version 24 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, China, Spain, Ireland
SPSS version 24 is a statistical software package developed by IBM. It provides a comprehensive set of tools for data analysis, including techniques for descriptive statistics, regression analysis, and predictive modeling. The software is designed to help users interpret data, identify trends, and make informed decisions based on statistical insights.

More about "Hypertriglyceridemia"

Hypertriglyceridemia is a metabolic condition characterized by elevated triglyceride levels in the bloodstream.
This disorder is often associated with an increased risk of cardiovascular disease and pancreatitis.
Effective research protocols are crucial for understanding and managing hypertriglyceridemia.
PubCompare.ai's AI-driven tool can optimize your research by easily locating relevant protocols from literature, preprints, and patents, while leveraging AI comparisons to identify the most reproducible and accurate approaches.
This can help improve your research outcomes and enhance your understanding of this condition.
Hypertriglyceridemia is also known as hyperlipidemia, hyperlipemia, or hypertriglyceridaemia.
It can be measured using various laboratory techniques, such as SAS version 9.4, SPSS version 22.0, AU680, Cobas c501, Elecsys 2010, Intralipid, KGE014, SAS 9.4, Cobas 8000 analyzer, and SPSS version 24.
Identifying and managing the underlying causes of hypertriglyceridemia, such as diet, lifestyle, and genetic factors, is crucial for effective treatment and prevention of associated complications.
PubCompare.ai's platform can assist researchers in optimizing their search for the most reliable and reproducible protocols, ultimately enhancing their understanding and management of this metabolic disorder.